Kollagenosis (Ehlers‑Danlos type VI)

What is Kollagenosis (Ehlers‑Danlos type VI)?

Kollagenosis, more commonly known as Ehlers‑Danlos syndrome type VI (EDS‑VI) or kyphoscoliotic type, is a rare inherited connective‑tissue disorder caused by a defect in the gene that produces the enzyme lysyl‑hydroxylase 1 (LH1). This enzyme is essential for proper collagen cross‑linking, the “glue” that gives skin, ligaments, blood vessels, and many organs their strength and elasticity. When LH1 is deficient, collagen fibers are weak and improperly formed, leading to the hallmark features of EDS‑VI: severe muscle weakness at birth, progressive joint laxity, fragile skin, and a tendency to develop early‑onset kyphoscoliosis (forward‑bending spine curvature).

EDS‑VI accounts for less than 1 % of all Ehlers‑Danlos cases and follows an autosomal recessive inheritance pattern, meaning a child must inherit two faulty copies of the PLOD1 gene—one from each parent—to develop the disease. Because the condition is so rare, many patients are initially misdiagnosed with other forms of EDS or with muscular dystrophy.

Common Causes

While the primary cause of Kollagenosis (EDS‑VI) is genetic, several related conditions or factors can mimic or exacerbate its presentation. The following list includes the most frequently encountered causes or contributors:

• Mutations in the PLOD1 gene – classic cause of EDS‑VI.
• Mutations in the FKBP14 gene – leads to a variant called “EDS‑VIIB” with similar features.
• Vitamin C deficiency (Scurvy) – impairs collagen hydroxylation and can produce skin fragility.
• Other Ehlers‑Danlos subtypes (e.g., classical, hypermobile) – share joint hypermobility and skin manifestations.
• Marfanoid habitus syndromes (e.g., Loeys‑Dietz) – overlapping connective‑tissue abnormalities.
• Congenital muscular dystrophies – early‑onset hypotonia may be confused with EDS‑VI.
• Progressive systemic sclerosis – skin tightening can mask underlying fragility.
• Chronic steroid use – weakens connective tissue and may worsen scoliosis.
• Traumatic injuries – repeated joint subluxations can mimic hereditary laxity.
• Environmental factors that increase oxidative stress (e.g., smoking) – may accelerate tissue damage in genetically predisposed individuals.

Associated Symptoms

Patients with EDS‑VI often experience a constellation of signs that evolve from infancy into adulthood. Common manifestations include:

• Congenital muscle weakness – newborns may have poor suck reflex and delayed motor milestones.
• Kyphoscoliosis – curvature of the spine often appears before age 5 and can progress rapidly.
• Joint hypermobility and recurrent subluxations – especially of the shoulders, hips, and knees.
• Skin findings – soft, velvety skin that bruises easily; atrophic scarring after minor trauma.
• Fragile blood vessels – leading to easy bruising, spontaneous hematomas, or arterial rupture in severe cases.
• Ocular involvement – myopia, lens subluxation, or retinal detachment.
• Cardiovascular abnormalities – mitral valve prolapse, aortic root dilation, or other connective‑tissue‑related heart issues.
• Dental problems – high‑arched palate, crowded teeth, and increased risk of periodontal disease.
• Gastrointestinal symptoms – constipation, hernias, or hiatal hernia due to lax abdominal wall.
• Neurological complaints – chronic pain, peripheral neuropathy, or headaches from cervical spine instability.

When to See a Doctor

Because many EDS‑VI features overlap with other disorders, early professional evaluation is crucial, especially when any of the following occur:

• Persistent muscle weakness or delayed motor milestones in an infant.
• Visible curvature of the spine that worsens over weeks or months.
• Frequent joint dislocations or subluxations without a clear injury.
• Unexplained easy bruising, large hematomas, or bleeding after minor bumps.
• Sudden chest, abdominal, or back pain that could indicate arterial or organ rupture.
• New onset of severe headaches, vision changes, or neurological deficits.
• Family history of Ehlers‑Danlos, early‑onset scoliosis, or unexplained arterial dissections.

If any of these signs are present, schedule an appointment with a geneticist, rheumatologist, or a connective‑tissue specialist promptly.

Diagnosis

Diagnosing EDS‑VI involves a combination of clinical evaluation, imaging, laboratory testing, and genetic analysis.

1. Detailed Medical & Family History

The clinician asks about developmental milestones, previous injuries, skin fragility, and any relatives with similar symptoms.

2. Physical Examination

• Assessment of joint range of motion and Beighton score for hypermobility.
• Skin examination for elasticity, translucency, and scarring.
• Muscle strength testing, especially in the trunk and proximal limbs.
• Spine evaluation for kyphosis or scoliosis.

3. Imaging Studies

• Radiographs (X‑rays) – to document scoliosis, vertebral anomalies, and joint subluxations.
• MRI – useful for cervical spine instability, spinal cord compression, or vascular assessments.
• Echocardiography – evaluates heart valves and aortic dimensions.

4. Laboratory Tests

• Urinary pyridinoline cross‑links – reduced in LH1 deficiency (research tool, not routine).
• Serum vitamin C level – to rule out scurvy‑related collagen defects.

5. Genetic Testing

The definitive test is a molecular analysis of the PLOD1 gene, which can be performed via next‑generation sequencing panels for connective‑tissue disorders or whole‑exome sequencing. Identifying two pathogenic variants confirms the diagnosis. Testing of parents determines carrier status.

6. Diagnostic Criteria

According to the 2017 International Classification of Ehlers‑Danlos Syndromes, a diagnosis of EDS‑VI requires:

• Demonstrated pathogenic variants in PLOD1 (or FKBP14 for the VIIB variant).
• Presence of congenital muscular hypotonia plus progressive kyphoscoliosis.
• At least three of the following: skin fragility, joint hypermobility, ocular involvement, or vascular complications.

Treatment Options

There is currently no cure for EDS‑VI, so management focuses on reducing complications, preserving function, and improving quality of life. A multidisciplinary team—geneticist, physiatrist, orthopedic surgeon, cardiologist, and physical therapist—is ideal.

Medical Interventions

• Vitamin C supplementation (500–1000 mg daily) – may enhance residual collagen hydroxylation; recommended based on limited data (Mayo Clinic).
• Beta‑blockers (e.g., propranolol) – sometimes used to reduce aortic root dilation progression.
• Analgesics & neuropathic pain agents – acetaminophen, NSAIDs, gabapentin or pregabalin for chronic pain.
• Orthopedic bracing – thoracolumbar sacral orthoses to control scoliosis progression.
• Surgical correction – spinal fusion for severe curvature, vascular surgery for aneurysms, or tendon repair for recurrent dislocations. Surgery carries higher risk of wound healing problems, so it is reserved for severe, function‑limiting deformities.
• Cardiovascular surveillance – beta‑blockers, regular echocardiograms, and referral to cardiovascular surgery if aortic dimensions exceed thresholds (American Heart Association guidelines).

Home & Lifestyle Management

• Physical therapy – low‑impact strengthening (e.g., swimming, pilates) to improve trunk stability while avoiding excessive joint stress.
• Occupational therapy – adaptive devices, joint protection strategies, and ergonomic modifications for daily activities.
• Skin care – gentle cleansing, moisturizers, and protective padding to prevent bruising and tearing.
• Nutrition – a balanced diet rich in antioxidants, protein, and collagen‑supporting nutrients (vitamin C, copper, zinc).
• Activity modification – avoid high‑impact sports, heavy lifting, and contact activities that heighten rupture risk.
• Psychological support – chronic pain and visible deformities can affect mental health; counseling or support groups are beneficial.

Prevention Tips

While the genetic basis of EDS‑VI cannot be prevented, certain measures can minimize complications and slow disease progression:

• Early genetic counseling for families with a known PLOD1 mutation.
• Regular monitoring of spinal curvature and cardiovascular status (every 6–12 months).
• Maintain optimal vitamin C intake through diet (citrus, berries, bell peppers) or supplements as advised.
• Use protective gear (knee pads, elbow guards) during physical activities.
• Adopt a fall‑prevention plan at home—non‑slip flooring, adequate lighting, and assistive devices if needed.
• Stay hydrated and avoid smoking, which impairs collagen cross‑linking and vascular health.
• Educate school personnel and employers about joint protection and the need for accommodations.

Emergency Warning Signs

Prompt medical attention can be lifesaving for vascular or spinal emergencies associated with EDS‑VI.

Sources: Mayo Clinic, Cleveland Clinic, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), American College of Medical Genetics and Genomics (ACMG) guidelines, International Classification of Ehlers‑Danlos Syndromes (2017), American Heart Association (2023), PMID: 30187270; PMID: 26898028.